
Exagen Inc (XGN) Stock Forecast & Price Target
Exagen Inc (XGN) Analyst Ratings
Bulls say
Exagen is on track to achieve an annual revenue run-rate of $70-73M by the end of 2026, with a projected 5-10% year-over-year revenue growth. This growth is driven by the success of the company's expanded sales force and new biomarker launches, which have led to a 10% increase in volume and a 1% increase in ASPs in the first quarter of 2026. The company's focus on diagnostic testing for chronic autoimmune diseases, combined with its pipeline of new tests and strong management team, make it an attractive investment opportunity for investors with a long-term outlook.
Bears say
Exagen is facing headwinds due to a significant loss of a direct bill account, which is expected to have a $25 impact on trailing-twelve-month average selling price (ASP) over the coming quarters. This is expected to reset the company's quarterly ASP to a new base and contribute to Y/Y ASP declines. Additionally, the company's goal of reaching a $500/test ASP may be delayed to 2H27, and continued low single-digit sequential growth in quarterly ASP is expected throughout 2026. As a result, the company's revenue and free cash flow may be impacted, leading to a lowered 2026 growth outlook and a decline in peer multiples, resulting in a lowered price target from $18 to $8.
This aggregate rating is based on analysts' research of Exagen Inc and is not a guaranteed prediction by Public.com or investment advice.
Exagen Inc (XGN) Analyst Forecast & Price Prediction
Start investing in Exagen Inc (XGN)
Order type
Buy in
Order amount
Est. shares
0 shares